UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549~~

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of ~~the~~The Securities and Exchange Act of 1934

~~Securities~~Date ~~Exchange~~of ~~Act~~Report (Date of ~~1934~~earliest event reported): January 30, 2019

~~Date~~Protect ofPharmaceuticals ~~Report (Date of earliest event reported): November 28TH, 2018~~Corporation

~~Protect~~(Exact ~~Pharmaceutical~~name ~~Corporation~~of registrant as specified in its charter)

(Exact Name of Registrant as Specified in Charter)

Nevada

000-54001

27-1877179

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

Nevada		000-54001		82-4148346
(State of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4876, Cecile Avenue, Las Vegas, NV	89115
(Address of principal executive offices)	(Zip Code)

~~Registrant’s telephone number, including area code: (~~954~~) 866~~-~~3726~~292-0033

(Registrant’s telephone number, including area code)

PROTECT PHARMACEUTICAL CORPORATION

95 Merrick Way, Third Floor, Coral Gables, Florida 33143

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item 1.01. Entry into a Material Definitive Agreement, and Item 1.02, Termination of A Material Definitive Agreement

~~Board~~As of 1/30/2019, the Shareholders and Board of Directors ~~Retainer~~voted ~~Agreement~~to

~~In connection with the appointment of Mr. Wajed Salem to the Board of Directors~~ (~~the “Board”~~i) ~~of Protect Pharmaceutical~~ ~~Corporation,~~Ratify aall ~~Nevada~~actions ~~corporation~~taken (the “Company”), as further discussed below in Item 5.02 of this Current Report on Form 8-K, on November 28th, 2018, the Company entered into a Board of Directors Retainer Agreement (the “Retainer Agreement”) with Mr. Salam, pursuant to which the Company agreed to pay Mr. Salam the following compensation for his services: 1,000,000 shares of the Company’s $.005 par value per share common stock (the “Common Stock”), for 4 years of service, with 25% of such Common Stock shares vesting at the end of each calendar year, with the first vesting date onby ~~December~~Una 31Taylor, ~~2019,~~CEO ~~as long as Mr. Salam remains a member of the Board~~ and continues to fulfill his duties and provide the services during the corresponding vesting period. Notwithstanding the foregoing, if Mr. Salam’s appointment is terminated prior to 4 years of service, at any time after the first vesting period, Mr. Salam will continue to earn the Common Stock shares in the agreed upon quantityPresident; however, the vesting period of the remaining Common Stock shares will then move to the end of the fourth calendar year, which would be December 31, 2022. However, the Board in its discretion, may at any time accelerate the vesting period for the Common Stock shares under the Retainer Agreement.

~~The~~(ii) ~~term~~Re-elect ~~of the Retainer Agreement is from the date of execution of same until Mr~~Ms. ~~Salam~~Taylor ~~either~~as ~~resigns~~Chief orExecutive isOfficer, ~~terminated~~President, ~~from~~and ~~such position~~Secretary, ~~in accordance with the Company’s Articles of Incorporation~~ and ~~Bylaws~~Ms. ~~Pursuant~~Taylor toand ~~the Retainer Agreement, the Company shall not pay~~ Mr. ~~Salam~~Wajed ~~any~~Salem ~~extra~~as ~~fees for each regularly scheduled meeting~~ Members of the Board ~~that~~of ~~he attends in person~~Directors, ~~nor for~~until ~~attending~~their ~~meetings~~successors ~~telephonically.~~may ~~Additionally, pursuant to the Retainer Agreement. The foregoing description of the Retainer Agreement does not purport to~~ be ~~complete~~named and is qualified ~~in its entirety by the Retainer Agreement, a copy of which is attached to this Current Report on Form 8-K as Exhibit 10~~.~~1, which is incorporated herein by reference.~~

(iii) Affirm certain transactions previously entered into by the Company and disaffirm certain transactions which may have been announced and reported but were never made final and legally binding on same.

A copy of the Shareholder’s Action Without Meeting, signed by Ms. Taylor as owner of 93% of all voting rights, sufficient to act without meeting as noted under the Company’s Bylaws and Nevada law, and a copy of the Board of Directors resolution, also sufficient for action without a meeting under the Company’s Bylaws and Nevada law, is attached to and made a part of this disclosure.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
10.1*		Director Retainer Agreement entered into between Protect Pharmaceutical Corporation. and Wajed Salam dated November 28, 2018.
Ex 1		Board Action Without Meeting of January 30, 2018
Ex 2		Board Action Without Meeting of January 30, 2019, Protect Pharmaceuticals Corporation
Ex 3		Board Ratification

*Filed herewith.2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: ~~December~~January 730, ~~2018~~2019

	Protect Pharmaceutical Corporation.

	By:	*/s/ Una Taylor*
	Name:	Una Taylor
	Title:	Chief Executive Officer

Filing Compare · PROTECT PHARMACEUTICAL Corp